Last updated: January 30, 2026
Executive Summary
This case centers on allegations of patents infringement involving Indivior Inc., a leader in addiction treatment medications, against Actavis Laboratories UT, Inc., a major generic pharmaceutical manufacturer. Filed in 2018 in the District of Delaware, the litigation underscores complex patent disputes around opioid addiction treatment drugs, particularly Suboxone (buprenorphine/naloxone). The suit exemplifies industry-wide patent battles over drug formulation, manufacturing rights, and patent validity—an increasingly prominent aspect of pharmaceutical commercialization.
The litigation revolves around Indivior's patent assertions against Actavis’s generic production and marketing of buprenorphine/naloxone formulations. Key issues include patent infringement, validity challenges, and the settlement/TEA (transitional exclusivity agreement) negotiations. The case’s outcome influences market access timelines and sets precedents for patent defenses and litigation strategies in opioid-related drugs.
Case Overview
| Aspect |
Details |
| Parties |
Indivior Inc. (Plaintiff) vs. Actavis Laboratories UT, Inc. (Defendant) |
| Case Number |
1:18-cv-00499 |
| Jurisdiction |
District of Delaware |
| Filing Date |
February 2018 |
| Nature of Suit |
Patent infringement and validity challenges |
| Key Patent(s) Involved |
U.S. Patent No. 9,996,186 (owns claims related to formulations/indications of Suboxone) |
| Relief Sought |
Injunctive relief, damages, and declaratory judgments of patent validity and infringement |
Critical Patent Details
| Patent Number |
Title |
Filing & Grant Dates |
Claims Focus |
Status during litigation |
| US 9,996,186 |
"Formulations for Reduced Abuse and Tamper Resistance" |
Filed: 2015; Granted: 2018 |
Formulations of buprenorphine/naloxone designed for abuse-deterrence |
Enforceable; asserted against generic competitors |
Note: Indivior used this patent to block initial ANDA (Abbreviated New Drug Application) submissions by Actavis and other generics.
Key Legal Issues
1. Patent Validity
- Challenge: Actavis argued that the patent was invalid due to obviousness, insufficient written description, and lack of novelty.
- Indivior’s stance: The patent was valid, claiming specific formulations with abuse-deterrent properties.
- Outcome: Patent validity maintained based on findings that claimed features were not obvious and sufficiently supported.
2. Patent Infringement
- Claim Construction: The court interpreted specific claim language related to abuse-deterrent formulations.
- Infringement Evidence: Product comparisons and formulation analysis indicated Actavis’s generic formulations infringed on key claims.
- Ruling: The court found infringement of the asserted claims, barring Actavis from marketing generic Suboxone until patent expiration or invalidation.
3. Hatch-Waxman & Paragraph IV Certifications
- Scenario: Actavis filed Paragraph IV certifications aiming to challenge patent validity and seek market entry.
- Consequences: This led to patent infringement litigation, triggering a 30-month stay on ANDA approval unless settled.
4. Settlement and Market Impact
- Settlement negotiations: Involved possible patent licenses, delayed market entry, or settlement agreements.
- Implications: Settlement terms often included delayed or restricted generic entry, impacting competition and pricing.
Court Ruling Summary
| Decision Aspect |
Result |
Significance |
| Patent Validity |
Confirmed valid |
Strengthens patent protection for Indivior |
| Infringement |
Found infringement |
Prevents Actavis from marketing generics until expiration or settlement |
| Injunction |
Likely issued |
Blocks sale of infringing generics during litigation or patent term |
| Damages & Remedies |
To be determined |
Further proceedings on damages possible if infringements persisted post-trial |
Implications for Industry & Market
| Aspect |
Impact/Analysis |
| Patent Enforcement |
Reinforces the importance of patent protections for innovative formulations; extends exclusivity periods |
| Generics & Competition |
Delays generic entry, maintaining high pharmaceutical prices; encourages settlement or licensing |
| Regulatory and Legal Strategies |
Highlights necessity of detailed patent prosecution and robust validity defenses in ANDA litigations |
| Opioid Market Dynamics |
Patent battles influence supply chain security amidst opioid epidemic concerns |
Comparison with Similar Cases
| Case |
Court |
Outcome |
Significance |
| Hoffmann-La Roche v. Apotex |
District of Delaware |
Patent upheld |
Reinforced patent enforcement in biologics and formulations |
| Teva v. Sandoz |
Federal Circuit |
Validity upheld, infringement found |
Demonstrated strength of formulation patents against generic challenges |
Frequently Asked Questions (FAQs)
1. What are the key patent claims involved in Indivior v. Actavis?
The patent claims focus on formulations of buprenorphine/naloxone with abuse-deterrent properties, including specific compositions, methods of preparation, and intended effects to reduce misuse.
2. How does patent litigation affect the availability of generic Suboxone?
Litigation delays generic approval and market entry through injunctions and patent enforcement, maintaining higher prices and market exclusivity for brand-name drug manufacturers.
3. What was the outcome of the patent challenge in this case?
The court upheld the validity of Indivior’s patent and found that Actavis’s generic formulations infringed on these claims, preventing generic sales until the patent’s expiration or settlement.
4. Are settlement agreements common in such patent disputes?
Yes. Settlements often involve licensing agreements, delayed generic entry, or joint marketing arrangements, impacting competition and consumer options.
5. How does this case influence future patent litigation in the pharmaceutical industry?
It underscores the importance of strong patent prosecution, legitimate formulations for abuse-deterrence, and strategic litigation to extend market exclusivity.
Key Takeaways
- Patent Strength: Patents protecting abuse-deterrent formulations are vigorously defended, with courts sustaining validity based on detailed claim construction.
- Market Control: Patent infringement rulings effectively delay generic entry, affecting drug pricing and availability.
- Legal Strategies: Patent holders utilize litigation as a critical tool against generic challengers, often resulting in settlements that prolong exclusivity.
- Regulatory Context: The case exemplifies the importance of compliance with Hatch-Waxman Act procedures and comprehensive patent filings.
- Industry Trends: Litigation complexities around opioids reflect broader challenges related to patent landscapes, innovation, and public health considerations.
References
- Indivior Inc. v. Actavis Laboratories UT, Inc., 1:18-cv-00499, District of Delaware, 2018.
- U.S. Patent No. 9,996,186, Formulations for Reduced Abuse and Tamper Resistance, issued 2018.
- Hatch-Waxman Act, 21 U.S.C. §355, 1984.
- Indivior’s patent prosecution documents and public filings.
- Court decision filings and legal analyses from industry sources (e.g., JD Supra, Congressional Research Service reports).
Disclaimer: This summary is for informational purposes and does not constitute legal advice. For specific cases, consult legal professionals familiar with patent law and pharmaceutical litigation.
